Journal
CANCERS
Volume 12, Issue 2, Pages -Publisher
MDPI
DOI: 10.3390/cancers12020261
Keywords
hepatocellular carcinoma; extracellular vesicles; liquid biopsy; drug delivery
Categories
Funding
- Associazione Laura Bassi Onlus, Pescara, Italy
Ask authors/readers for more resources
Hepatocellular carcinoma (HCC) is the sixth most common cancer and the third highest cause of mortality from cancer, largely because of delays in diagnosis. There is currently no effective therapy for advanced stage HCC, although sorafenib, the standard treatment for HCC, systemic therapy (including tyrosine kinase inhibitors and anti-angiogenesis agents), and more recently, immunotherapy, have demonstrated some survival benefit. The measurement and modification of extracellular vesicle (EVs) cargoes-composed of nucleic acids, including miRNAs, proteins, and lipids-holds great promise for future HCC diagnosis, prognosis, and treatment. This review will provide an overview of the most recent findings regarding EVs in HCC, and the possible future use of EVs as liquid biopsy-based biomarkers for early diagnosis and as a vehicle for targeted drug-delivery.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available